Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 137 resultados
LastUpdate Última actualización 01/05/2026 [09:09:00]
pdfxls
Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days
previousPage Resultados 50 a 75 de 137 nextPage  

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE

NºPublicación:  EP4717171A2 01/04/2026
Solicitante: 
I SENS INC [KR]
i-Sens, Inc
EP_4717171_A2

Resumen de: EP4717171A2

According to the present disclosure, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.

MULTI-ANALYTE MONITORING SENSOR

NºPublicación:  EP4718067A1 01/04/2026
Solicitante: 
SHENZHEN SISENSING CO LTD [CN]
EP_4718067_PA

Resumen de: EP4718067A1

The present disclosure describes a multi-analyte monitoring sensor, which includes a substrate, a working electrode disposed on the substrate, an enzyme sensing layer disposed on the working electrode, and a polymer membrane layer disposed on the enzyme sensing layer; The working electrode includes a first working electrode and a second working electrode; The enzyme sensing layer includes a first analyte enzyme layer and a second analyte enzyme layer, the first analyte enzyme layer is disposed on the first working electrode and the second analyte enzyme layer is disposed on the second working electrode, the first analyte is glucose, and the second analyte is ketone; The polymer membrane layer is permeable to both the first analyte and the second analyte and covers the first analyte enzyme layer and the second analyte enzyme layer. Thus, a sensor with high sensitivity and simplified processing for continuous monitoring of blood glucose and blood ketones can be provided

DEPLOYMENT AND USE OF A CONTINUOUS ANALYTE MONITORING SYSTEM FOR IMPROVED PATIENT TREATMENT

NºPublicación:  MX2026002435A 01/04/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
ABBOTT DIABETES CARE INC.
WO_2025050085_A1

Resumen de: MX2026002435A

Disclosed herein are system, method, and computer program product embodiments for improving detection and treatment of patient conditions based on continuous analyte data. The disclosed techniques utilize analyte data, such as lactate, glucose, and creatinine, provided from a continuous analyte sensor to predict patient outcomes. The prediction may also take into account other medical information associated with the patient, such as patient vital signs and medical history. The disclosed system allows for early and non-invasive prediction of patient outcomes in various settings including a hospital setting, a home setting, disease (e.g., heart failure, sepsis) detection, and high risk surgery monitoring. The disclosed system also is configured to monitor patient conditions and generating alerts and/or notifications based on the predicted patient outcomes to provide preemptive treatment of patient conditions.

DETERMINING A CONCENTRATION OF GLUCOSE IN A SUBJECT'S BLOOD

NºPublicación:  MX2025015650A 01/04/2026
Solicitante: 
AFON TECH LTD [GB]
AFON TECHNOLOGY LTD
GB_2631280_PA

Resumen de: MX2025015650A

According to an aspect, there is provided a computer-implemented method (200) of determining a concentration of glucose in a subject's blood, the method comprising: acquiring (202) first measurement data indicative of a response resulting from an electromagnetic (EM) signal interacting with the subject's blood in a body part of the subject; acquiring (204) second measurement data indicative of at least one parameter associated with the subject; and using (206) a predictive model to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data, the predictive model having been trained to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data.

Pattern discovery in continuous glucose monitoring data

NºPublicación:  US12588838B1 31/03/2026
Solicitante: 
VERILY LIFE SCIENCES LLC [US]
Verily Life Sciences LLC
US_12588838_B1

Resumen de: US12588838B1

Introduced here are diabetes management platforms able to examine glucose measurements associated with a subject to discover patterns indicative of similar behaviors/circumstances. More specifically, a diabetes management platform can acquire multiple data series generated by a glucose monitoring device that monitors the blood glucose level of an individual over multiple time intervals. The diabetes management platform can then apply a similarity algorithm to produce a distance measure (also referred to as a “similarity measure”) for each data series. For example, the diabetes management platform may, for each data series, perform dynamic time warping to produce a distance measure with respect to each of the other data series. The diabetes management platform can identify patterns indicative of similar behaviors/circumstances based on these distance measures.

SYSTEMS FOR PROVIDING PROFESSIONAL TREATMENT GUIDANCE FOR DIABETES PATIENTS

NºPublicación:  ES3060889T3 30/03/2026
Solicitante: 
TIGAR HEALTH INC
EP_1000000_PA

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

SITE TRACKING BASED ON CONNECTIVITY IN INFUSION PUMP SYSTEMS

NºPublicación:  US20260083911A1 26/03/2026
Solicitante: 
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc
US_20260083911_A1

Resumen de: US20260083911A1

Enclosed herein are methods and systems for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, and a smartphone or other multi-purpose consumer electronic device (i.e., remote control device). Communications among these devices can be coordinated to ensure reliable and consistent transmission of medical data.

METHOD OF DETERMINING GLUCOSE CONCENTRATION IN TISSUE, COMPUTER PROGRAM PRODUCT, RADIOMETER AND A SYSTEM THEREFOR

NºPublicación:  AU2024351716A1 26/03/2026
Solicitante: 
MEDISENSONIC SPOLKA AKCYJNA
MEDISENSONIC SPOLKA AKCYJNA
AU_2024351716_PA

Resumen de: AU2024351716A1

A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention involves use of the radio noise signal is measured using a passive radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.

SYSTEMS FOR DETERMINING SIMILARITY OF SEQUENCES OF GLUCOSE VALUES

NºPublicación:  US20260083358A1 26/03/2026
Solicitante: 
DEXCOM INC [US]
Dexcom, Inc
US_20260083358_A1

Resumen de: US20260083358A1

In implementations of systems for determining a similarity of sequences of glucose values, a computing device implements a similarity system to receive input data describing a sequence of user glucose values measured by a continuous glucose monitoring (CGM) system. The similarity system computes similarity scores for a plurality of sequences of glucose values by comparing each glucose values included in the sequence of user glucose values with ever glucose value included in each sequence of the plurality of sequences. A particular sequence of glucose values that is associated with a highest similarity score is identified. The similarity system determines an externality associated with the particular sequence. The similarity system generates an indication of the externality for display in a user interface.

SYSTEM AND METHOD TO PREDICT GLUCOSE RESPONSE

NºPublicación:  WO2026062700A1 26/03/2026
Solicitante: 
DECIPHER HEALTH INC [IN]
DECIPHER HEALTH INC
WO_2026062700_A1

Resumen de: WO2026062700A1

The present disclosure relates to a system and method to predict the post- prandial glucose response in the individuals type 2 diabetes mellitus (T2DM) in India by taking sample of patients with T2DM from various locations across India and fitting them with continuous glucose monitors (CGM) and calculating the postprandial glucose response based on the different meal intakes by the patients. The present disclosure further relates to the utilization of k-means clustering models to classify food types based on nutritional information and classification of patients. The present disclosure also relates to utilizing XGBoost to predict postprandial blood glucose responses based on patient phenotypes and food categories and providing personalized recommendations taking into account meal type, preferences, and regional influences which would allow patients with T2DM to eat and drink foods to maintain their blood sugar within prescribed limits and prevent disease progression.

METHOD FOR CONTROLLING BLOOD GLUCOSE AND ARTIFICIAL PANCREAS SYSTEM FOR CARRYING OUT THE METHOD

NºPublicación:  AU2024331938A1 26/03/2026
Solicitante: 
UNIV POLITECNICA DE VALENCIA
UNIVERSITAT POLIT\u00C8CNICA DE VAL\u00C8NCIA
AU_2024331938_A1

Resumen de: WO2025046158A1

The invention relates to a method for controlling glucose in a flexible-structure bihormonal artificial pancreas that manages optional meal and/or exercise alerts by means of coordinated control actions, comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate ingestion as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) according to an insulin bolus that has been administered; defining a corrected incremental plasma glucose y̅(s), a corrected insulin infusion ū(s) and a corrected carbohydrate ingestion d̅(s); defining a virtual control action μ(s), divided between regulatory actions μ r and counterregulatory actions μ cr ; and calculating the control actions using a 2-DOF feedback controller with a prefilter having a nominal value F r (s).

SYSTEM AND METHOD FOR CALCULATING AN INSULIN DOSING FUNCTION

NºPublicación:  US20260083909A1 26/03/2026
Solicitante: 
UNIV OF VIRGINIA PATENT FOUNDATION [US]
University of Virginia Patent Foundation
US_20260083909_A1

Resumen de: US20260083909A1

A reinforcement learning process with self attention is used for insulin dosing decisions in an automated medical system. The State-Action-Reward-Next State (SARS) sequence is used. The state represents the current condition, including recent continuous glucose monitoring readings, insulin doses, meal information, and potentially other relevant factors like time of day or physical activity levels. Based on this state, the agent takes an action by deciding on an insulin dose. It then receives a reward, a numerical value quantifying the quality of the action, based on resulting glucose levels and their proximity to the target range. This leads to a new state, and the process repeats. Through this iterative process, the algorithm updates the neural network weights, allowing the agent to learn which actions lead to better outcomes in different states.

METHODS OF TREATING EYE DISORDERS

NºPublicación:  WO2026064554A1 26/03/2026
Solicitante: 
KODIAK SCIENCES INC [US]
KODIAK SCIENCES INC
WO_2026064554_A1

Resumen de: WO2026064554A1

Provided herein are methods of treating various eye disorders, including, for example, wet age-related macular degeneration (wAMD) or diabetic retinopathy (DR), using an anti-VEGF therapy, such as an anti-VEGF antibody conjugate.

AMBULATORY GLUCOSE PROFILE (AGP) INTELLIGENT INTERPRETATION AND INSULIN ADJUSTMENT METHOD BASED ON EXPERT SYSTEM

NºPublicación:  US20260088171A1 26/03/2026
Solicitante: 
NORTHEASTERN UNIV [CN]
SHANGHAI SIXTH PEOPLES HOSPITAL [CN]
Northeastern University,
Shanghai Sixth People's Hospital
US_20260088171_A1

Resumen de: US20260088171A1

An ambulatory glucose profile (AGP) intelligent interpretation and insulin adjustment method based on an expert system includes: establishing a knowledge base in an inference mechanism; constructing an interpretation and decision support expert system with a simplified expert system architecture based on the knowledge base; constructing a patient problem analysis tree in three dimensions of hypoglycemia, blood glucose fluctuation, and hyperglycemia of patients; expanding each rule with expert AGP interpretation and empirical data; constructing a basal insulin dosage adjustment rule and a mealtime insulin dosage adjustment rule based on an interval type-2 fuzzy expert system; and adjusting a node of the patient problem analysis tree based on the interpretation and decision support expert system and a group of the patient, and providing a decision suggestion in combination with the basal insulin dosage adjustment rule and the mealtime insulin dosage adjustment rule.

LUMINESCENT ENZYME-BASED SENSORS

NºPublicación:  US20260083363A1 26/03/2026
Solicitante: 
TERUMO CARDIOVASCULAR SYSTEMS CORP [US]
Terumo Cardiovascular Systems Corporation
US_20260083363_A1

Resumen de: US20260083363A1

This document describes medical systems for detecting biological analytes. For example, this document describes sensors for the continuous monitoring of biological analytes, such as glucose and/or lactate, in aqueous solutions and body fluids (e.g., blood) based on a readout of fluorescence or luminescence signals.WO

Multi-Head Convolutional Network for Average Glucose Prediction

NºPublicación:  US20260083357A1 26/03/2026
Solicitante: 
GOOGLE LLC [US]
Google LLC
US_20260083357_A1

Resumen de: US20260083357A1

Systems and methods for determining a glucose value for a user are disclosed herein. The method includes receiving a plurality of data inputs associated with biometric data of the user, the plurality of data inputs including at least one data input representative of a past estimated glucose value of the user and processing the plurality of data inputs with a multi-headed temporal convolutional neural network to generate a blood glucose value for the user. The method also includes providing a notification to the user based at least in part on the blood glucose value.

DIABETES MANAGEMENT PARTNER INTERFACE FOR WIRELESS COMMUNICATION OF ANALYTE DATA

NºPublicación:  US20260089162A1 26/03/2026
Solicitante: 
DEXCOM INC [US]
Dexcom, Inc
US_20260089162_A1

Resumen de: US20260089162A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.

ADJUSTMENT OF MEDICAMENT DELIVERY BY A MEDICAMENT DELIVERY DEVICE BASED ON MENSTRUAL CYCLE PHASE

NºPublicación:  US20260083912A1 26/03/2026
Solicitante: 
INSULET CORP [US]
INSULET CORPORATION
US_20260083912_A1

Resumen de: US20260083912A1

Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.

INFUSION SYSTEMS AND METHODS FOR PATIENT ACTIVITY ADJUSTMENTS

NºPublicación:  US20260088150A1 26/03/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC
US_20260088150_A1

Resumen de: US20260088150A1

Techniques disclosed herein relate to operating a fluid delivery device in a personalized manner based at least in part on historical data of a patient. In some embodiments, the techniques involve obtaining historical meal data for the patient associated with historical meal events for the patient; determining a meal content based at least in part on the historical meal data; obtaining nutritional information associated with the meal content and historical meal events for the patient; determining, by a control system, a dosage of insulin based at least in part on the nutritional information and the historical meal events; and operating, by the control system, an actuation arrangement of the infusion device to deliver the dosage of the insulin to the patient.

MEDICINE INJECTION AND DISEASE MANAGEMENT SYSTEMS, DEVICES, AND METHODS

NºPublicación:  EP4715554A2 25/03/2026
Solicitante: 
BIGFOOT BIOMEDICAL INC [US]
Bigfoot Biomedical, Inc
EP_4715554_A2

Resumen de: EP4715554A2

One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.

MEAL MONITORING DEVICE AND METHOD THEREOF

NºPublicación:  EP4715836A1 25/03/2026
Solicitante: 
I SENS INC [KR]
i-Sens, Inc
EP_4715836_PA

Resumen de: EP4715836A1

A meal monitoring apparatus according to an embodiment of the present invention includes a data receiving unit configured to receive measurement data of parameters related to an ear of a target object and blood glucose data of the target object; a first estimated time calculating unit configured to calculate a first estimated time estimated as a food intake activity time of the target object based on the measurement data; a second estimated time calculating unit configured to calculate a second estimated time estimated as a glucose absorption time of the target object based on the blood glucose data; and a meal time calculating unit configured to calculate a meal time of the target object based on the first estimated time and the second estimated time.

CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE

NºPublicación:  ES3060256T3 25/03/2026
Solicitante: 
MYLIFE DIABETES CARE AG
mylife Diabetes Care AG
EP_4671882_PA

Resumen de: EP4671882A2

The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.

Systems and methods for patient monitoring using an HCP-specific device

NºPublicación:  AU2026201602A1 19/03/2026
Solicitante: 
DEXCOM INC
Dexcom, Inc
AU_2026201602_A1

Resumen de: AU2026201602A1

Systems and methods disclosed provide ways for Health Care Professionals (HCPs) to be involved in initial patient system set up so that the data received is truly transformative, such that the patient not just understands what all the various numbers mean but also how the data can be used. For example, in one implementation, a CGM device is configured for use by a HCP, and includes a housing and a circuit configured to receive a signal from a transmitter coupled to an indwelling glucose sensor. A calibration module converts the received signal into clinical units. A user interface is provided that is configured to display a measured glucose concentration in the clinical units. The user interface is further configured to receive input data about a patient level, where the input data about the patient level causes the device to operate in a mode appropriate to the patient level. ar a r

SENSOR SYSTEM WITH IMPROVED GLUCOSE VALUE ESTIMATES

NºPublicación:  WO2026060397A2 19/03/2026
Solicitante: 
DEXCOM INC [US]
DEXCOM, INC
WO_2026060397_A2

Resumen de: WO2026060397A2

An analyte sensor system may include an analyte sensor configured to generate a raw sensor signal associated with an analyte concentration of a host. Sensor electronics may be configured to generate estimated analyte values from the raw sensor signal, determine a rate of change for the estimated analyte values or the raw signal, determine a working electrode temperature, and determine an elapsed time since sensor insertion. The sensor electronics may improve sensor performance by determining a prediction horizon as a function of at least one of the elapsed time and the working electrode temperature, determining a time-lag- compensated estimated analyte value for one of the estimated analyte values as a function of the determined prediction horizon and the rate-of-change, and adjusting estimated analyte values by applying a correction that is a function of the estimated analyte values.

GLUCOSE MONITORING DEVICE

Nº publicación: US20260076628A1 19/03/2026

Solicitante:

CUSTOM TYPEONE LLC [US]
Custom TypeOne LLC

US_20260076628_A1

Resumen de: US20260076628A1

A system is provided comprising external device(s), tracking device(s) configured to generate blood glucose level data for tracked individual(s), and an alert device for management of alerts generated at the external device(s). The alert device comprises processor(s) and memory device(s). The memory device(s) comprise computer readable code that, when executed by the processor(s), causes the processor(s) to receive input data comprising blood glucose level data received from the tracking device(s), to determine an alert setting for an alert to be generated at an external device of the external device(s) based on the input data, and to generate a signal that causes the alert to be generated at the external device. The alert setting includes an identification of the external device where the alert is to be generated, an alert magnitude, and/or the alert type, with the alert type including an audible alert, a haptic alert, and/or a visual alert.

traducir